These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7081138)

  • 1. Current status of chemotherapy, hormonal therapy, and immunotherapy in the treatment of renal cell carcinoma.
    Poster DS; Bruno S; Penta JS; Pinna K; Vilk P; Macdonald JS
    Am J Clin Oncol; 1982 Feb; 5(1):53-60. PubMed ID: 7081138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced renal cell carcinoma.
    deKernion JB; Lindner A
    Prog Clin Biol Res; 1982; 100():641-59. PubMed ID: 6183675
    [No Abstract]   [Full Text] [Related]  

  • 4. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [the oral use of a progestational hormone (Provera 100) as an adjuvant in therapy of adenocarcinoma of the kidney. Preliminary report].
    Liberti M; Di Silverio F; Concolino G; Tenaglia R; Marocchi A
    Minerva Urol; 1980; 32(3):175-8. PubMed ID: 7432332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for renal cell carcinoma.
    Amato RJ
    Semin Oncol; 2000 Apr; 27(2):177-86. PubMed ID: 10768596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical aspects and chemotherapy of adenocarcinoma of the kidney].
    Possinger K; Hartenstein R; Ehrhart H
    Fortschr Med; 1981 Mar; 99(12):419-23. PubMed ID: 7227939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of metastatic renal cell carcinoma.
    Peterson LJ
    Compr Ther; 1977 Feb; 3(2):20-4. PubMed ID: 837655
    [No Abstract]   [Full Text] [Related]  

  • 10. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
    Brinkmann OA; Bruns F; Prott FJ; Hertle L
    Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy for renal cell carcinoma.
    Jacobsohn KM; Wood CG
    Semin Oncol; 2006 Oct; 33(5):576-82. PubMed ID: 17045086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for metastatic renal cell carcinoma.
    Wirth MP
    Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive treatment of renal cell carcinoma.
    Pontes JE
    Int Adv Surg Oncol; 1983; 6():309-22. PubMed ID: 6874085
    [No Abstract]   [Full Text] [Related]  

  • 15. New agents for the treatment of renal cell carcinoma.
    Tian GG; Dawson NA
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):546-54. PubMed ID: 12113087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of IL-2.
    Sznol M; Parkinson DR
    Oncology (Williston Park); 1994 Jun; 8(6):61-7; discussion 67, 71, 74-5. PubMed ID: 7521197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drug therapies for advanced renal cell carcinoma.
    Gore ME; Harrison ML; Montes A
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.